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In Brief
Glucose-stimulated insulin secretion can
be regulated by glucagon and GLP-1
receptors on paracrine b-cells. Svendsen
et al. find that complete blockade of
glucagon signaling in islets severely limits
insulin secretion but establish that
paracrine glucagon signaling involves
both the glucagon and GLP-1 receptors.
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The intra-islet theory states that glucagon secretion
is suppressed when insulin secretion is stimulated,
but glucagon’s role in intra-islet paracrine regulation
is controversial. This study investigated intra-
islet functions of glucagon in mice. We examined
glucagon-induced insulin secretion using isolated
perfused pancreata from wild-type, GLP-1 receptor
(GLP-1R) knockout, diphtheria toxin-induced proglu-
cagon knockdown, b cell-specific glucagon receptor
(Gcgr) knockout, and global Gcgr knockout (Gcgr/)
mice. We found that glucagon stimulates insulin
secretion through both Gcgr and GLP-1R. Moreover,
loss of either Gcgr or GLP-1R does not change insu-
lin responses, whereas combined blockage of both
receptors significantly reduces insulin secretion.
Active GLP-1 is identified in pancreatic perfusate
from Gcgr/ but not wild-type mice, suggesting
that b cell GLP-1R activation results predominantly
from glucagon action. Our results suggest that com-
bined activity of glucagon and GLP-1 receptors is
essential for b cell secretory responses, emphasizing
a role for paracrine intra-islet glucagon actions to
maintain appropriate insulin secretion.
INTRODUCTION
Glucose homeostasis is primarily regulated by the hormones
insulin and glucagon, secreted from the pancreatic islets of
Langerhans. Although insulin produced by b cells is the blood
glucose-lowering hormone, glucagon secreted from a cells
acts as the major counter-regulatory hormone to insulin and is
important for maintaining normal glucose levels. Conversely,
glucagon secretion is regulated by glucose, being inhibited dur-
ing hyperglycemia and stimulated during hypoglycemia, result-
ing in stimulation of hepatic glucose output (Gromada et al.,
2007). Disturbed control of a cell function is characteristic of
type 2 diabetes and, importantly, results in hyperglucagonemia,
which contributes to hyperglycemia (Kahn, 2003; Kazda et al.,Cell Re
This is an open access article under the CC BY-N2016; Knop et al., 2007). The development of hyperglucagone-
mia would be consistent with the so-called intra-islet hypothesis
stating that glucagon secretion undergoes inhibition from insulin,
which, in conditions with decreased insulin secretion or a cell in-
sulin resistance, would lead to reduced suppression of glucagon
secretion (Banarer et al., 2002; Hope et al., 2004; Meier et al.,
2006). On the other hand, glucagon is also known as an effica-
cious stimulator of insulin secretion, and the glucagon receptor
is located on both pancreatic b and d cells (Adriaenssens et al.,
2016), suggesting that glucagon might have direct effects on in-
sulin and somatostatin secretion.
In this study we investigate mechanisms regulating intra-islet
communication, focusing on the role of glucagon in control of
insulin secretion using the perfused mouse pancreas, a model
that allows investigations of the paracrine relationships within
intact islets. We employed a range of complementary genetic
and pharmacological approaches to disrupt local glucagon
signaling. Thus, to acutely eliminate glucagon secretion from a
cells, we used diphtheria toxin (DT)-induced destruction of pro-
glucagon-producing a cells (Pedersen et al., 2013). For estima-
tion of the importance of glucagon receptors (Gcgrs) in b cells,
we used a mouse line with inducible Gcgr knockout exclusively
in b cells (Gcgrbcell/) as well as mice with global knockout of
the Gcgr (Gcgr/) (Gelling et al., 2003). The functional impor-
tance of the glucagon-like peptide-1 receptor (GLP-1R) was
investigated using Glp1r/ mice (Scrocchi et al., 1996) as well
as the GLP-1R antagonist exendin(9-39) (Ex9).
RESULTS
Exogenous Glucagon Stimulates Insulin Secretion
through the Glucagon and GLP-1 Receptors
In pilot studies using the perfused mouse pancreas, we
observed that glucagon was only able to stimulate insulin secre-
tion at elevated (12 mM) glucose levels, whereas no response
was observed at 3.5 mM glucose (Figures S1A and S1B). Thus,
the effect of exogenous glucagon was examined further only at
high glucose levels. Infusions of glucagon (0.1–10 nM) stimulated
insulin secretion in a dose-dependent manner with 2.0- to
3.7-fold increases (Figure 1). Glucagon infusions (1–10 nM)
were still able to increase insulin secretion, albeit from a lower
baseline, in the presence of the co-administered GLP-1Rports 25, 1127–1134, October 30, 2018 ª 2018 The Authors. 1127
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
antagonist Ex9 (Figures 1A and 1C) or in perfused pancreata
from Glp1r/ mice (Figures 1B and 1D). Pancreata from mice
with selective inactivation of the Gcgr only in b cells (Gcgrbcell/)
showed similar levels (versus control) of insulin secretion in
response to 1–10 nM glucagon (Figures 1E and 1G).
On the other hand, pancreata from mice with global Gcgr
knockout (Gcgr/ mice) only increased insulin secretion in
response to 10 nM glucagon and with a submaximal response
relative to the control group, whereas lower doses of glucagon
had no effect on insulin secretion (Figures 1F and 1H), consistent
with the very high local concentrations of glucagon (see below).
Combining blockade of glucagon and GLP-1 receptor by simul-
taneous addition of Ex9 in perfusions of Gcgr/ mice
completely abolished the insulin responses to glucagon and
glucose (Figures 1F and 1H).
Disruption of Endogenous Glucagon Signaling Reduces
Insulin Secretion
Differentmethodsof selective or completedisruptionof glucagon
signaling were used in four different mouse strains to investigate
the effect of endogenousglucagonon insulin secretion. In all con-
trolmice, switching from low (3.5mM) to high (12mM)glucose led
to an 4.5-fold increase in insulin (p < 0.05) and a simultaneous
drop in glucagon secretion (3-fold, p < 0.05) (Figure 2). Secre-
tion of hormones was further stimulated by arginine infusion,
except for insulin secretion at low glucose levels.
To investigate insulin secretion in islets with depletion of
glucagon from a cells, we used DT-Gcg mice. Total glucagon
output from these pancreata was significantly reduced
compared with control mice, reflecting successful ablation of
a cell mass (p < 0.001; Figure 2A). Insulin responses (Figures
2B and 2G) to increased glucose concentrations and arginine
were significantly reduced after a cell ablation and reduction
of islet glucagon secretion (p < 0.01). DT had no effect in
wild-type mice (Figure S2).
Mice with knockout of the Gcgr exclusively in b cells showed a
pattern of glucagon and insulin secretion in response to glucose
and arginine similar to that obtained using pancreata from cre
control mice (Figures 2C, 2D, and 2H).
In pancreata from Gcgr/ mice (Figure 2E), glucagon secre-
tionwasmarkedly elevated by up to 26-fold comparedwith litter-
mate controls. Insulin secretion was significantly stimulated
in Gcgr/ mice by infusion of arginine and high glucose and
increased compared withGcgr+/+mice. To determine the contri-
bution of the GLP-1R, we infused Ex9, which significantly
reduced insulin secretion in response to high glucose and argi-
nine inGcgr/micecomparedwith experimentswithout Ex9, re-
sulting in an3-fold reduction in total insulin output (p < 0.001). In
control mice, Ex9 tended to reduce the insulin response to high
glucose levels, but arginine induced a similar increase in insulin
levels in the presence or absence of Ex9 (Figures 2F and 2I).
The GLP-1 Receptor Antagonist Exendin(9-39) Inhibits
Both GLP-1- and Glucagon-Mediated cAMP Responses
via the GLP-1 Receptor
The ability of glucagon and GLP-1 to activate mouse Gcgr and
GLP-1R was examined in non-islet cells transiently expressing
the receptors. Glucagon and GLP-1 activated their respective1128 Cell Reports 25, 1127–1134, October 30, 2018receptors with potencies in the sub-nanomolar range (half
maximal effective concentration [EC50] of 0.23 ± 0.09 nM and
0.15 ± 0.11 nM, respectively) (Figures 3A and 3B). Furthermore,
glucagon acted as a weak agonist on the GLP-1R (EC50 = 36.4 ±
0.22 nM), approaching the maximal response (Emax) of GLP-1
on the GLP-1R (88% activation compared with GLP-1) (Fig-
ure 3A). In contrast, only glucagon, but not GLP-1, activated
the Gcgr (Figure 3B), consistent with previous findings (Jorgen-
sen et al., 2007).
We next verified the relative selectivity of Ex9 for the GLP-1R.
As expected, increasing concentrations of Ex9 resulted in a
decrease in GLP-1-induced cyclic AMP (cAMP) accumulation
via the GLP-1R with an half maximal inhibitory concentration
(IC50) value of 12 ± 0.47 nM (Figure 3C). Ex9 was also able to
abrogate glucagon-mediated cAMP responses via the GLP-1R
with the same IC50 value of 12 ± 0.44 nM (Figure 3C). It was, how-
ever, not able to inhibit glucagon-stimulated cAMP responses
mediated through the Gcgr (Figure 3D). Addition of Ex9 reduced
the GLP-1 and glucagon-mediated cAMP levels below the basal
levels, indicating that Ex9 also acts as an inverse agonist on the
GLP-1R, as suggested previously (Serre et al., 1998).
Exendin 9-39 Reduces Insulin Secretion from the
Perfused Mouse Pancreas
We further evaluated the direct effect of Ex9 on basal insulin
secretion by perfusion with Ex9. Addition of Ex9 significantly
reduced insulin secretion in pancreata from control and Gcgr/
mice at high glucose levels, whereas no significant effect was
observed in Glp1r/ mice, confirming that Ex9 is specific for
the GLP-1 receptor (Figures 4A and 4B).
Pancreatic GLP-1 Immunoreactivity
Considerable evidence suggests that, under some circum-
stances, the pancreas produces immunoreactive and bioactive
GLP-1 (Marchetti et al., 2012; Taylor et al., 2013), which
may contribute to a local incretin axis (Chambers et al., 2017).
Accordingly, we evaluated whether fully processed active
GLP-1 (7-36NH2/37) is secreted from perfused pancreata of
Gcgr/ and Gcgr+/+ mice (Figure 4C). Secretion of fully pro-
cessed intact GLP-1 was very low in control mice (0–2 pM at
low and high glucose) and often below the assay detection limit.
Secretion of intact GLP-1 was significantly higher from Gcgr/
pancreata (5.5-fold in total output; Figure 4C). Simultaneous
perfusion of the pancreas with a DPP4 inhibitor (valine-pyrroli-
dide) did not change the levels of active GLP-1 in control or
Gcgr/ mice (Figure 4C), suggesting that DPP4-induced
GLP-1 degradation is negligible in the perfusedmouse pancreas.
DISCUSSION
The interplay between glucagon and insulin secretion has been
the subject of many studies, and the prevailing concept reflects
the ‘‘intra-islet hypothesis’’ that insulin inversely regulates
glucagon secretion. This hypothesis would be consistent with
the theory of core-to-mantle blood flow, with b cells reacting to
changes first and mantle cells (a and d cells) then responding
to insulin (Bonner-Weir and Orci, 1982; Maruyama et al., 1984).
However, other studies have suggested that blood flow rather
Figure 1. Exogenous Glucagon Infusions Stimulate Insulin Secretion through the Glucagon and the GLP-1 Receptor in Perfused Mouse
Pancreata
(A, B, E, and F) Insulin secretion from perfused pancreata during infusion of glucagon (0.1–10 nM) at 12 mM glucose in control mice with or without Ex9 (A, n = 8),
Glp1r/ mice (B, n = 6), Gcgrbcell/ mice (E, n = 5), and global Gcgr/ mice with or without Ex9 (F, n = 8).
(C, D, G, and H) Mean insulin output averaged over 10 min before and during addition of glucagon to perfused pancreata of control mice (C), Glp1r–/– (D),
Gcgrbcell-/- (G), and Gcgr-/- (H) mice. Significance was tested by 1-way ANOVA (repeatedmeasures) comparing stimulated output versus respective basal output.
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S1.
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Figure 2. Effect of Disrupted Glucagon Signaling on Hormone Secretion from Perfused Mouse Pancreata
(A–F) Insulin and glucagon secretion from DT-Gcg (A and B, n = 8),Gcgrbcell/ (C and D, n = 5), andGcgr/mice with or without addition of Ex9 (E and F; n = 8).
(G–I) Mean insulin output averaged over 5min before and during addition of glucose and arginine to perfused pancreata from control mice (G), Gcgrbcell-/- mice (H),
and Gcgr-/- mice (I). Significance was tested by 1-way ANOVA with post hoc Tukey modifications. Data are shown as mean ± SEM. **p < 0.01, ***p < 0.001.
See also Figure S2.perfuses the islet from one side to the other regardless of cell
type, thereby providing for paracrine actions of a and d cell
secretion on downstream b cells (Kharouta et al., 2009; Liu
et al., 1993; Nyman et al., 2008). Exogenous glucagon is thought
to stimulate insulin secretion, but endogenous glucagon is not1130 Cell Reports 25, 1127–1134, October 30, 2018classically considered part of the paracrine b cell network (Kawa-
mori et al., 2009; Leung et al., 2006; Ravier and Rutter, 2005).
In this study, we revisited intra-islet paracrine relationships. An
alternative approach to understanding intra-islet relationships
is to use the isolated perfused pancreas preparations as
Figure 3. Activation and Inhibition of Glucagon and GLP-1
Receptors
(A and B) cAMP accumulation in COS-7 cells transfected with the mouse
GLP-1 receptor (A) or glucagon receptor (B) after treatment with increasing
concentrations of GLP-1 and glucagon.
(C and D) cAMP accumulation after increasing concentrations of Ex9 in the
presence of fixed concentrations of GLP-1 (C) or glucagon (C and D) in COS-7
cells transfected with the mGLP-1 receptor (C) and glucagon receptor (D). The
dotted line represents basal receptor activity in the absence of agonist.
Data are shown as mean ± SEM, n R 3 independent experiments run in
triplicates.opposed to the often used isolated islet or in vivo studies. This
technique allows functional interrogation of islet secretory activ-
ity without interference from other organs in the body, excluding
systemic factors, elimination and/or degradation of hormones,
etc., which often complicates interpretation of in vivo studies.
Importantly, the perfused pancreas maintains its local cytoarch-
itecture and microvasculature, ensuring normal flux of both sub-
strates and products to and from the various cell types.
Glucagon was described as an insulin secretagogue as early
as 1965 (Samols et al., 1965). Our studies extend these findings
by demonstrating that this is a direct effect mediated by distinct
receptors in the mouse pancreas. Previous experiments on iso-
lated b cells clearly show that glucagon is capable of directly
stimulating insulin secretion, and b cells (and d cells) have been
reported to express Gcgrs (Adriaenssens et al., 2016; Huypens
et al., 2000; Van Schravendijk et al., 1985). A paracrine role for
glucagon in the regulation of insulin secretion is supported
by observations from other groups using mouse models with
Gcgr or glucagon deficiencies (Gelling et al., 2003, 2009; Moens
et al., 1998; Sørensen et al., 2006).
Our data clearly demonstrate that glucagon can activate the
GLP-1R, although with a lower potency compared with its inter-
action with the Gcgr. The ability of glucagon to make use of the
GLP-1R in the absence of functional Gcgrs becomes apparent inGcgrbcell/ mice, where insulin secretion was similar to that
of control mice. In Gcgr/ mice, only high doses of glucagon
were able to stimulate insulin secretion, again through the
GLP-1R. Conversely, without a functional GLP-1R (whether
blocked by an antagonist or in the Glp1r/ mouse pancreas),
exogenous glucagon still induced a rise in insulin secretion,
although the response was slightly reduced compared with
that in animals with fully functional GLP-1R and Gcgr.
A role for pancreatic GLP-1 has been discussed, and studies
have suggested local production of GLP-1 in islets (Marchetti
et al., 2012; Taylor et al., 2013; Whalley et al., 2011). The original
concept was that GLP-1 results from posttranslational process-
ingof proglucagon viaPC1/3 in intestinal L-cells,whereasproglu-
cagon in the pancreas is cleaved by PC2, yielding glucagon and
the major proglucagon fragment. Nevertheless, studies using
Pdx1-Cre to control the expression of Gcg and, hence, GLP-1
in the mouse pancreas suggested that pancreas-derived
GLP-1maycontribute substantially to the incretin effect following
oral glucose administration in mice (Chambers et al., 2017). In
contrast, our data demonstrate that the levels of active, fully pro-
cessed GLP-1(7-36NH2/7-37) in perfused pancreata from control
mice are very low and frequently undetectable. Indeed, a recent
study based on very sensitive detection methods was unable to
identify measurable amounts of GLP-1 in extracts of the normal
mouse pancreas (Galsgaard et al., 2018). Hence, under normal
circumstances, the secretion of active GLP-1 from the pancreas
is negligible. However, we show here that GLP-1R-stimulated in-
sulin secretion can also be elicited by glucagon and, therefore,
does not require the presence of locally produced islet GLP-1.
Hence, the inhibition of insulin secretion by Ex9, as demonstrated
by Chambers et al. (2017) and also evident from our data, may
reflect inhibition of glucagon-induced activation of the GLP-1R
as well as blockade of excess GLP-1 produced in the context
of selective pancreatic reactivation of Gcg expression.
The Gcgr/ mouse has massive hyperglucagonemia associ-
atedwith postnatal enlargement of the pancreas and hyperplasia
of the islets, primarily a cells and, to a lesser extent, d cells (Gel-
ling et al., 2003). Perfusion of Gcgr/ pancreata demonstrated
significant levels of active GLP-1, showing that, in conditions
with highly increased secretory activity, a cell hyperplasia, and
perhaps activation of a cell Pcsk1, bioactive GLP-1 is locally
produced. A recent paper showed that, under normal circum-
stances, islet GLP-1 is not necessary for normal insulin secretion
but could play a role during metabolic stress and increased
secretory demands (Traub et al., 2017). Further studies are
needed to define the conditions enabling processing and secre-
tion of bioactive GLP-1 in islet cells.
The indisputable effect of the GLP-1R becomes obvious in
the Gcgr/ pancreas, where we noted an unexpected increase
in insulin secretion. However, the combination of excessive
glucagon secretion as well as increased levels of active GLP-1
could lead to increased activation of the GLP-1Rs in b and d cells
and, therefore, increased hormone secretion. Notably, GLP-1
blockade through Ex9 in Gcgr/ pancreata completely abol-
ished augmentation of insulin secretion, attesting to the impor-
tance of these two receptors for insulin secretion.
Attempting to further elucidate the role of glucagon and activa-
tion of the Gcgr without the influence of GLP-1, we used DT-GcgCell Reports 25, 1127–1134, October 30, 2018 1131
Figure 4. Role of GLP-1 Receptor Inhibition
and Intra-islet GLP-1 Secretion in Perfused
Mouse Pancreata
(A) Insulin secretion at 12 mM glucose after infu-
sion of Ex9 in control mice.
(B) Mean insulin output was averaged over 10 min
before and during addition of Ex9 to the perfused
pancreas of control, Gcgr/, and Glp-1r/ mice
at 12 mM glucose. Significance was tested by
1-way ANOVA (repeated measures) comparing
insulin secretion with and without Ex9 (n = 4,
**p < 0.01).
(C) Intact GLP-1 (7-36NH2/37) secretion in
perfused pancreas fromGcgr+/+ andGcgr/mice
with and without a DPP4 inhibitor (ValPyr).
Data are represented as mean ± SEM.mice with acute knockdown of all proglucagon products. This
mouse model has previously been shown previously to have a
normal total islet area as well as b cell area compared with con-
trol mice (Pedersen et al., 2013). The reduced insulin secretion
after glucagon knockdown suggests that glucagon may play a
regulatory role in insulin secretion. Glucagon-dependent insulin
secretion was only apparent at high glucose levels, indicating
that intra-islet glucagon is particularly required at times with
high insulin secretion demand. It could be speculated that
glucose-stimulated insulin secretion also more generally de-
pends on glucagon levels; thus, when glucagon is low, less
insulin is needed to maintain appropriate blood glucose.
A stimulating effect of glucagon on insulin secretion at low
glucose levels would be inexpedient, if not dangerous, given glu-
cagon’s role in the defense against hypoglycemia.
The results from these mouse models with different ways
of disrupting glucagon signaling independently support the
concept that some degree of local glucagon activity is required
for appropriate insulin secretion. Thus, we have demonstrated
an important role for glucagon acting directly within the pancreas
on the secretion of islet hormones. Furthermore, it is clear that
glucagon activates both the glucagon and the GLP-1 receptor
on b cells and that experimental inhibition of the effect of
glucagon requires simultaneous inhibition of the two receptors,
which should be taken into consideration when trying to eliminate
glucagon action by only blocking the Gcgr. Likewise, the use
of GLP-1 receptor antagonists not only blocks the actions of
GLP-1 but also any potential action of glucagon on GLP-1 recep-
tors, which should be brought tomindwhen formulating concepts
linking a-cell secretory products to control of a cell function.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All experiments were conducted in compliance with animal experiment license (2008/561-1491) issued by the Danish Committee for
Animal Research, and approved by the local animal welfare committee at the University of Copenhagen. Mice generated in Toronto
were approved by the Mt. Sinai Hospital Animal Care Committee.
Studies were conducted in animals 8-16 weeks of age on a C57BL6/J background, and included sex- and age-matched littermate
control mice. Mice were housed up to eight per cage and kept on 12hr light-dark cycle with free access to chow diet and water.
Different mouse strains were used in this study:
1) Inducible knockdown of proglucagon-producing cells (DT-Gcg; ((Pedersen et al., 2013)) where expression of the human DT
receptor is driven by the proglucagon promoter, and DT injections lead to 90% destruction of proglucagon producing cells.
The mice received ip injections of 10 ng DT/g body weight on day 1, 3, and 5.
2) Micewith inducible Gcgr knockout specifically in b-cells (Gcgrbcell/) were generated bymatingMIP-cremice (Campbell et al.,
2016) withGcgr flox mice (Longuet et al., 2013). MIP-Cre (controls) orGcgrbcell/mice were treated with 50 mg/kg Tamoxifen
ip for 5 consecutive days, then allowed to recover for several weeks prior to use in perfusion studies.
3) Glp1r/ mice with global deletion of the GLP-1 receptor (Scrocchi et al., 1996).
4) Gcgr/ mice with global Gcgr knockout (Gelling et al., 2003).
METHOD DETAILS
Cell lines and transfection
COS-7 cells (ATCC, Virginia, USA) were cultured in DMEM1885 (10%FBS, 2mMglutamine, 180 units/ml penicillin, and 45 g/ml strep-
tomycin (10% CO2 and 37
C)) and transiently transfected with mouse Gcgr or mouse GLP-1 receptor DNA (Origene, Rockville, MA,Cell Reports 25, 1127–1134.e1–e2, October 30, 2018 e1
USA (MC203290 and MC216256, respectively) using the calcium phosphate precipitation method with addition of chloroquine
(Kissow et al., 2012; Luthman and Magnusson, 1983). DNA was diluted in TE-buffer (10 mM Tris–HCl and 1 mM EDTA, pH 7.5)
to which 2M CaCl2 was added. The DNA-calcium coprecipitate was added to equal amount of HEPES-buffered saline (HBS). Trans-
fection mixture was added to the cells and incubated for 5 h (37C, 10%CO2). cAMP assays were performed48 h after termination
of transfection procedure.
cAMP assay
Transiently transfected COS-7 cells expressing either Gcgrs or GLP-1 receptors were incubated with GLP-1 or glucagon for
30 minutes at 37C and assayed for cAMP accumulation. To test for antagonism of Ex9, cells were preincubated for 10 minutes
with Ex9 followed by incubation with constant concentrations of either GLP-1 or glucagon corresponding to 50%–80% of the
maximal cAMP accumulation response (Emax) on the GLP-1 receptor or Gcgr, respectively. Luminescence was measured by Perkin
ElmerTM EnVision 2104 Multilabel Reader (Skovlunde, Denmark). All experiments were performed in triplicates and repeated at least
three times.
Perfused mouse pancreas
Pancreas perfusions were performed as previously described (Adriaenssens et al., 2016). Briefly, mice were anaesthetized with ip
injection of ketamine (90mg/kg; Ketaminol Vet.; MSD Animal Health, Madison, NJ, USA) and xylazine (10 mg/kg; Rompun Vet; Bayer
Animal Health, Leverkusen, Germany). The intestine, spleen, stomach, and kidneys were tied off. The aorta was ligated proximally to
the celiac artery, and a catheter was inserted into the aorta providing arterial perfusion with a modified Krebs-Ringer bicarbonate
buffer (Adriaenssens et al., 2016). Effluent samples were collected through a catheter in the portal vein. The perfusion system
(UP-100 universal perfusion system, Hugo Sachs Elektronik, March-Hugstetten, Germany) maintained constant flow of 1.35 ml/min,
perfusion buffer was heated and oxygenated (95%O2, 5%CO2) and pressure was monitored throughout the experiment
(40-50 mmHg). Experiments exhibiting significant changes in pressure or flow (> 20%) were terminated and discarded.
Experimental protocol
After surgery and perfusion with medium was initiated, the pancreas was allowed to stabilize for 30 minutes.
Protocol a
In a series of experiments, different concentrations of glucagon (0.1, 1, 10nM) were infused for 10min at 12mM glucose separated by
20min periods to allow secretion to return to basal level. This protocol was repeated in wild-type,Gcgrbcell/,Glp1r/, andGcgr/
male mice with or without 1mM Ex9 added to the perfusion buffer.
Protocol b
In a second set of experiments, the pancreas was perfused at low glucose (3.5mM) followed by a switch to high glucose (12 mM) in
the perfusion buffer. In all experiments, L-arginine (10 mM, Sigma-Aldrich) was infused as stimulus for 5 min periods during both
glucose concentrations.
Hormone measurements
Hormone concentrations in the perfusion effluent were measured using in-house radioimmunoassays. Glucagon was measured
using a COOH-terminally directed antiserum (4305), which measures fully processed glucagon as well as N-terminally extended
molecular forms (Orskov et al., 1991). Insulin was measured using an antibody crossreacting strongly with rodent insulin I and II
(2006-3; (Brand et al., 1995)). Intact GLP-1 was measured using a sandwich ELISA for active GLP-1 (Vilsbøll et al., 2003).
QUANTIFICATION AND STATISTICAL ANALYSIS
The statistical procedures used and exact values of n are indicated in the figure legends. Responses to arginine and glucagon infu-
sions were evaluated by comparing hormone secretion for 5 or 10 minutes prior to infusion with hormone output during the infusion
period using one-way ANOVA analysis. Statistical analyses were performed using GraphPad Prism v.7. Data are expressed as
mean ± SEM, and statistical significance was accepted when p < 0.05.e2 Cell Reports 25, 1127–1134.e1–e2, October 30, 2018
